皮肌炎并发恶性肿瘤一例
A Case of Dermatomyositis Complicated with Malignant Tumors
DOI: 10.12677/ACM.2022.12111476, PDF,   
作者: 陈亚娟:济宁医学院临床医学院,山东 济宁;王玉忠*:济宁医学院附属医院全科医学科,山东 济宁
关键词: 特发性炎性肌病(IIMs)皮肌炎(DM)恶性肿瘤皮肤肌酶Idiopathic Inflammatory Myopathy (IIMs) Dermatomyositis (DM) Malignant Tumor Skin Muscle Enzymes
摘要: 特发性炎性肌病(IIMs),简称肌炎,以骨骼肌无力和慢性炎症为特征。其他器官也经常受累,包括皮肤、心脏、胃肠道和肺。根据临床和组织病理学发现的差异,已经确定了不同的IIM亚型,传统上分为多发性肌炎(PM)、皮肌炎(DM)和散发性包涵体肌炎(sIBM)。其中皮肌炎(DM)是一种多因素慢性自身免疫性疾病,具有特征性的皮肤变化,累及不同器官系统,包括肌肉、血管、关节、食管和肺,其种常见的肌外表现包括各种心脏异常、间质性肺疾病(ILD)和恶性肿瘤。DM与特定的恶性肿瘤有很强的相关性,包括卵巢癌、肺癌、胰腺癌、胃癌和结直肠癌。本文概述了皮肌炎的临床表现、治疗以及与恶性肿瘤的相关性。
Abstract: Idiopathic inflammatory myopathies (IIMs), referred to as myositis, characterized by skeletal mus-cle weakness and chronic inflammation. Other organs are often involved, including skin, heart, gas-trointestinal tract and lungs. According to the different clinical and histopathological findings, dif-ferent IIM subtypes have been identified, traditionally divided into multiple myositis (PM), derma-tomyositis (DM) and sporadic inclusion body myositis (sIBM). Dermatomyositis (DM) is a chronic autoimmune disease, has the characteristic of skin changes, involving different organ systems, in-cluding muscles, blood vessels, joints, esophagus and lung, and its common muscle performances include a variety of cardiac abnormalities, interstitial lung diseases (ILD) and malignant tumor. DM is strongly associated with specific malignancies, including ovarian, lung, pancreatic, gastric and colorectal cancers. This article summarized the clinical manifestation, treatment of dermatomyo-sitis and the correlation with malignant tumor.
文章引用:陈亚娟, 王玉忠. 皮肌炎并发恶性肿瘤一例[J]. 临床医学进展, 2022, 12(11): 10235-10240. https://doi.org/10.12677/ACM.2022.12111476

参考文献

[1] DeWane, M.E., Waldman, R. and Lu, J. (2020) Dermatomyositis: Clinical Features and Pathogenesis. American Acade-my of Dermatology, 82, 267-281. [Google Scholar] [CrossRef] [PubMed]
[2] Bogdanov, I., Kazandjieva, J., Darlenski, R. and Tsankov, N. (2018) Dermatomyositis: Current Concepts. Clinics in Dermatology, 36, 450-458. [Google Scholar] [CrossRef] [PubMed]
[3] Chu, L.L. and Rohekar, G. (2019) Dermatomyositis. Ca-nadian Medical Association Journal, 191, E340. [Google Scholar] [CrossRef] [PubMed]
[4] Findlay, A.R., Goyal, N.A. and Mozaffar, T. (2015) An Overview of Polymyositis and Dermatomyositis. Muscle & Nerve, 51, 638-656. [Google Scholar] [CrossRef] [PubMed]
[5] Maraví, T.Z., Burgos, P.I. and Prieto-González, S. (2020) Manifestaciones Clínicas y Anticuerpos Asociados y Específicos de Miositis en 15 Pacientes Chilenos con Dermatomiositis: Serie Clínica en un Centro Universitario [Clinical Manifestations and Antibody Profile in 15 Patients with Dermatomyositis]. Revista médica de Chile, 148, 160-167. [Google Scholar] [CrossRef] [PubMed]
[6] Kume, A., Kashiwakuma, D., Kubodera, A., et al. (2021) Monoclonal B-Cell Lymphocytosis Exacerbated by Prednisolone Therapy for Dermatomyositis. Internal Medicine, 60, 2853-2858. [Google Scholar] [CrossRef] [PubMed]
[7] Leung, A.K.C., Lam, J.M., Alobaida, S., Leong, K.F. and Wong, A.H.C. (2021) Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management. Current Pediatric Reviews, 17, 273-287. [Google Scholar] [CrossRef] [PubMed]
[8] Pinal-Fernandez, I. and Mammen, A.L. (2018) Der-matomyositis Etiopathogenesis: A Rebel Soldier in the Muscle. Current Opinion in Rheumatology, 30, 623-629. [Google Scholar] [CrossRef
[9] Bolko, L., Gitiaux, C. and Allenbach, Y. (2019) Derma-tomyosites Nouveaux Anticorps, Nouvelle Classification. [Dermatomyositis: New Antibody, New Classification]. Med-ical Sciences (Paris), 35, 18-23. [Google Scholar] [CrossRef] [PubMed]
[10] Bodoki, L., Nagy-Vincze, M., Griger, Z. and Dankó, K. (2015) Der-matomyositisspezifische Antikörper [Dermatomyositis-Specific Antibodies]. Zeitschrift für Rheumatologie, 74, 363-369. [Google Scholar] [CrossRef] [PubMed]
[11] Lauinger, J., Ghoreschi, K. and Volc, S. (2021) Characteristics of Dermatomyositis Patients with and without Associated Malignancy. Journal der Deutschen Dermatologischen Gesell-schaft, 19, 1601-1611. [Google Scholar] [CrossRef] [PubMed]
[12] Udkoff, J. and Cohen, P.R. (2016) Amyopathic Dermatomyositis: A Con-cise Review of Clinical Manifestations and Associated Malignancies. American Journal of Clinical Dermatology, 17, 509-518. [Google Scholar] [CrossRef] [PubMed]
[13] Orton, C., Topham, C. and Madigan, L.M. (2022) Paraneoplastic Dermatomyositis. The American Journal of Medicine, 135, 969-971. [Google Scholar] [CrossRef] [PubMed]
[14] Schlecht, N., Sunderkötter, C., Niehaus, S. and Nashan, D. (2020) Update on Dermatomyositis in Adults. Journal der Deutschen Dermatologischen Gesellschaft, 18, 995-1013. [Google Scholar] [CrossRef] [PubMed]
[15] Gkegkes, I.D., Minis, E.E. and Iavazzo, C. (2018) Dermatomyositis and Colorectal Cancer: A Systematic Review. Irish Journal of Medical Science, 187, 615-620. [Google Scholar] [CrossRef] [PubMed]
[16] Tripathi, R. and Fernandez, A.P. (2021) Characteristics of Hos-pitalized Dermatomyositis Patients with Underlying Malignancy: A Nationally Representative Retrospective Cohort Study. Archives of Dermatological Research, 313, 473-482. [Google Scholar] [CrossRef] [PubMed]
[17] Garg, T., Sanke, S., Chander, R., Agarwal, M., Agarwal, K. and Kumar, A. (2017) A Case of Dermatomyositis with Underlying Unusual Malignancy. Indian Journal of Dermatology, Venereology, and Leprology, 83, 473-476. [Google Scholar] [CrossRef] [PubMed]
[18] Lau, L., Huang, L., Fu, E., Tan, T.C., Kong, K.O. and Lim, M.Y. (2021) Nasopharyngeal Carcinoma in Dermatomyositis. Clinical Otolaryngology, 46, 1082-1088. [Google Scholar] [CrossRef] [PubMed]